A Study to Evaluate the Safety and Efficacy of RQC for AMD
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is evaluating whether a combination of resveratrol, quercetin, and curcumin is safe and effective for people with age-related macular degeneration.
Will I have to stop taking my current medications?
The trial requires that you stop taking any anticoagulant medication (blood thinners) at least 5 days before starting the study. For other medications, the protocol does not specify if you need to stop taking them.
Is the treatment generally safe for human use?
Research indicates that various forms of turmeric and curcumin, including tetrahydrocurcuminoids and CuminUP60®, are generally safe for human use. Studies have shown no concerns regarding genotoxicity (damage to genetic information) and have established safe consumption levels. For example, tetrahydrocurcuminoids are considered safe at 140 mg/day for adults, and CuminUP60® has a no observed adverse effect level (NOAEL) of 1000 mg/kg body weight per day in rats.12345
How does the treatment with Curcumin, Quercetin, and Resveratrol differ from other treatments?
This treatment is unique because it combines natural compounds known for their antioxidant and anti-inflammatory properties, which may help in managing various conditions. Curcumin, derived from turmeric, has been extensively studied for its potential to regulate inflammation and oxidative stress, while Quercetin and Resveratrol are known for their roles in protecting cells from damage and supporting cardiovascular health. This combination may offer a novel approach by targeting multiple pathways involved in disease processes.26789
What data supports the effectiveness of the drug curcumin?
Research shows that curcumin, a compound found in turmeric, has anti-inflammatory and antioxidant properties, which may help in managing chronic diseases like diabetes and certain cancers. However, its low solubility and bioavailability in the body can limit its effectiveness as a treatment.28101112
Who Is on the Research Team?
Paul A Knepper, MD, PhD
Principal Investigator
Zaparackas Knepper, Ltd
Zibute Zaparackas, MD
Principal Investigator
Zaparackas Knepper, Ltd
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either RQC or curcumin alone for AMD over 24 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Curcumin
- Quercetin
- Resveratrol
Curcumin is already approved in United States, European Union, India, China for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Paul A Knepper, MD PhD
Lead Sponsor